Digitally quantified area of residual tumor after neoadjuvant chemotherapy in HER2-positive breast cancer.

IF 4 3区医学 Q1 OBSTETRICS & GYNECOLOGY

Breast Cancer Pub Date : 2025-07-01 Epub Date: 2025-04-02 DOI:10.1007/s12282-025-01694-7

Mao Uematsu, Hiromichi Nakajima, Hirohiko Miyake, Masashi Wakabayashi, Chikako Funasaka, Chihiro Kondoh, Kenichi Harano, Nobuaki Matsubara, Ako Hosono, Yoichi Naito, Naoya Sakamoto, Motohiro Kojima, Tatsuya Onishi, Genichiro Ishii, Toru Mukohara

{"title":"Digitally quantified area of residual tumor after neoadjuvant chemotherapy in HER2-positive breast cancer.","authors":"Mao Uematsu, Hiromichi Nakajima, Hirohiko Miyake, Masashi Wakabayashi, Chikako Funasaka, Chihiro Kondoh, Kenichi Harano, Nobuaki Matsubara, Ako Hosono, Yoichi Naito, Naoya Sakamoto, Motohiro Kojima, Tatsuya Onishi, Genichiro Ishii, Toru Mukohara","doi":"10.1007/s12282-025-01694-7","DOIUrl":null,"url":null,"abstract":"Background: The area of residual tumor (ART) is a quantitative method for assessing tumors after neoadjuvant chemotherapy (NAC). This study evaluated whether ART can identify a favorable prognosis group in patients with HER2-positive surgically resected breast cancer and residual tumors post-NAC.Methods: We retrospectively reviewed patients with HER2-positive who underwent surgery after NAC, including trastuzumab, from 2005 to 2022 at our institution. ART was assessed at the maximum cut surface of the residual primary tumor using digital pathology images. Receiver operating characteristic curve analysis determined ART-Low and ART-High cutoffs, excluding ART-0 (0 mm2) patients.Results: Of the 219 patients, 82 had ART greater than 0 mm2. The median follow-up was 90.2 months. The number of patients in the ART-0, ART-Low (0 < ART ≤ 4.0 mm2), and ART-High (> 4.0 mm2) groups were 137, 39, and 43, respectively. The ART-Low group showed significantly shorter event-free survival compared to the ART-0 group (HR 3.50, 95% CI 1.52-8.06), and the ART-High group also tended toward poorer prognosis (HR 2.31, 95% CI 0.89-5.97). However, there was no significant difference in prognosis between the ART-Low and ART-High groups.Conclusions: The current study suggests that even minimal residual tumor cells in the primary site can significantly impact on prognosis in HER2-positive early breast cancer.","PeriodicalId":56083,"journal":{"name":"Breast Cancer","volume":" ","pages":"716-727"},"PeriodicalIF":4.0000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12174267/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12282-025-01694-7","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/2 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The area of residual tumor (ART) is a quantitative method for assessing tumors after neoadjuvant chemotherapy (NAC). This study evaluated whether ART can identify a favorable prognosis group in patients with HER2-positive surgically resected breast cancer and residual tumors post-NAC.

Methods: We retrospectively reviewed patients with HER2-positive who underwent surgery after NAC, including trastuzumab, from 2005 to 2022 at our institution. ART was assessed at the maximum cut surface of the residual primary tumor using digital pathology images. Receiver operating characteristic curve analysis determined ART-Low and ART-High cutoffs, excluding ART-0 (0 mm²) patients.

Results: Of the 219 patients, 82 had ART greater than 0 mm². The median follow-up was 90.2 months. The number of patients in the ART-0, ART-Low (0 < ART ≤ 4.0 mm²), and ART-High (> 4.0 mm²) groups were 137, 39, and 43, respectively. The ART-Low group showed significantly shorter event-free survival compared to the ART-0 group (HR 3.50, 95% CI 1.52-8.06), and the ART-High group also tended toward poorer prognosis (HR 2.31, 95% CI 0.89-5.97). However, there was no significant difference in prognosis between the ART-Low and ART-High groups.

Conclusions: The current study suggests that even minimal residual tumor cells in the primary site can significantly impact on prognosis in HER2-positive early breast cancer.

查看原文本刊更多论文

her2阳性乳腺癌新辅助化疗后残留肿瘤的数字量化面积。

背景：残存肿瘤面积（area of residual tumor， ART）是评价新辅助化疗（NAC）后肿瘤的一种定量方法。本研究评估ART是否能在手术切除的her2阳性乳腺癌和nac后残留肿瘤患者中确定一个预后良好的组。方法：我们回顾性分析了2005年至2022年在我院接受NAC手术的her2阳性患者，包括曲妥珠单抗。利用数字病理图像对残余原发肿瘤的最大切面进行ART评估。受试者工作特征曲线分析确定ART-Low和ART-High截止值，不包括ART-0 （0 mm2）患者。结果：219例患者中，ART≥0 mm2的有82例。中位随访时间为90.2个月。ART-0、ART-Low（0 2）和ART-High （> 4.0 mm2）组分别为137例、39例和43例。与ART-0组相比，ART-Low组的无事件生存期明显缩短（HR 3.50, 95% CI 1.52-8.06）， ART-High组的预后也倾向于较差（HR 2.31, 95% CI 0.89-5.97）。然而，ART-Low组和ART-High组的预后无显著差异。结论：目前的研究表明，在her2阳性的早期乳腺癌中，即使是最小的原发部位残留肿瘤细胞也会显著影响预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Breast Cancer ONCOLOGY-OBSTETRICS & GYNECOLOGY

CiteScore

6.70

自引率

2.50%

发文量

105

审稿时长

6-12 weeks

期刊介绍： Breast Cancer, the official journal of the Japanese Breast Cancer Society, publishes articles that contribute to progress in the field, in basic or translational research and also in clinical research, seeking to develop a new focus and new perspectives for all who are concerned with breast cancer. The journal welcomes all original articles describing clinical and epidemiological studies and laboratory investigations regarding breast cancer and related diseases. The journal will consider five types of articles: editorials, review articles, original articles, case reports, and rapid communications. Although editorials and review articles will principally be solicited by the editors, they can also be submitted for peer review, as in the case of original articles. The journal provides the best of up-to-date information on breast cancer, presenting readers with high-impact, original work focusing on pivotal issues.